Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Eisai, Johns Hopkins University's BSI enter into licensing agreement for GCPII technology

Eisai, Johns Hopkins University's BSI enter into licensing agreement for GCPII technology

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer

Genta initiates new dose-ranging study of tesetaxel drug

Genta initiates new dose-ranging study of tesetaxel drug

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

AAN guideline evaluates drugs’ safety and efficacy for treatment of muscle cramps

Genta commences Phase 2 trial of tesetaxel on first subject

Genta commences Phase 2 trial of tesetaxel on first subject

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

VELCADE sNDA receives FDA approval

VELCADE sNDA receives FDA approval

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Pfizer announces results from studies evaluating neratinib

Pfizer announces results from studies evaluating neratinib

University of Maryland School of Nursing to spearhead new Center for Pain Studies

University of Maryland School of Nursing to spearhead new Center for Pain Studies

VERTICAL Phase II trial results for NHL released

VERTICAL Phase II trial results for NHL released

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

Encouraging data from Seattle Genetics' phase I trial of brentuximab vedotin

New three-drug combination may be effective for treating patients with bone cancer

New three-drug combination may be effective for treating patients with bone cancer

Researchers explore optimal induction therapies for managing blood cancer

Researchers explore optimal induction therapies for managing blood cancer

VELCADE based regimens are cost-effective for payers and patients, finds study

VELCADE based regimens are cost-effective for payers and patients, finds study

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Tibotec Therapeutics'  INTELENCE granted FDA traditional approval

Tibotec Therapeutics' INTELENCE granted FDA traditional approval

Breast cancer patients treated with chemotherapy drug Taxol more likely to develop chronic neuropathic pain

Breast cancer patients treated with chemotherapy drug Taxol more likely to develop chronic neuropathic pain

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.